Solesta is a minimally invasive, biocompatible tissue bulking agent, indicated for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy.  It is administered as four injections in an office-based procedure via anoscopy.

The clinical studies supporting Solesta demonstrated both a dramatic reduction in the number of fecal incontinence episodes as well as durability up to 24 months.  In those studies, patients had significantly better control of their bowel movements, fewer leaks, and more days without accidents.  Additional studies are ongoing and our office will be participating as an open label, post-FDA approval site to further evaluate Solesta‚Äôs efficacy.

The most common risks of treatment associated with Solesta are mild or moderate pain or discomfort in the rectum, and minor to moderate bleeding or spotting from the rectum following treatment.  A few patients experienced a fever, abdominal pain, or diarrhea or constipation after treatment.  Most of these side effects were mild or moderate and resolved within two weeks.